H.C. Wainwright raised its price target for Alpha Cognition Inc. to $20 from $18. The firm maintained its Buy rating on the stock.
The revision follows second-quarter 2026 revenue of approximately $6 million. This performance surpassed the analyst's forecast of $4.7 million.
Strong sales of ZUNVEYL, a treatment for Alzheimer's disease, drove the quarterly beat. H.C. Wainwright subsequently increased its revenue projections for the full years 2026 and 2027.
The firm highlighted impressive revenue growth and gross profit margins as primary drivers for the update. Alpha Cognition continues to operate at a net loss while scaling its commercial infrastructure.